RecruitingPhase 1NCT06809400

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Sponsor

Eli Lilly and Company

Enrollment

127 participants

Start Date

Feb 18, 2025

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.

Eligibility

Min Age: 30 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This is a Phase 1 study testing a new investigational drug called LY4006896 to see if it is safe and how the body processes it. The study includes both healthy volunteers and people with a specific condition. **You may be eligible if...** - You are a healthy adult or have the specific condition being studied - You meet the age and health requirements of the trial - You are willing to undergo study procedures and monitoring **You may NOT be eligible if...** - You have significant other health conditions - You are pregnant, breastfeeding, or planning to become pregnant - You are taking medications that could interact with the study drug Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY4006896

Administered intravenously (IV)

DRUGPlacebo

Administered IV

Locations(14)

Collaborative Neuroscience Network - CNS

Los Alamitos, California, United States

Collaborative Neuroscience Network - CNS

Los Alamitos, California, United States

K2 Medical Research, LLC

Maitland, Florida, United States

Aqualane Clinical Research

Naples, Florida, United States

Charter Research

Orlando, Florida, United States

Progressive Medical Research

Port Orange, Florida, United States

K2 Medical Research, LLC

The Villages, Florida, United States

Charter Research

The Villages, Florida, United States

QUEST Research Institute

Farmington Hills, Michigan, United States

PPD Development, LP

Austin, Texas, United States

Evergreen Health Research

Kirkland, Washington, United States

Inland Northwest Research

Spokane, Washington, United States

P-One Clinic

Hachiōji, Japan

Oita University Hospital

Yufu, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06809400

Related Trials

tDCS on Parkinson's Disease Cognition

NCT030253341 location

Brain Training to Improve Balance in Parkinson's Disease

NCT059866431 location

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

NCT034574931 location

World Data on Ambroxol for Patients With GD and GBA Related PD

NCT043889693 locations

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT0668083070 locations